2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Clinical Procedures, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Transplantation, Non-Biological Therapies, Chemotherapy, Radiation Therapy, Adverse Events, Biological Processes, Immune Mechanism, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Patient Safety, Practice Models, Quality Improvement, Diseases, Bleeding and Clotting, Immunology, GVHD, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Research, AML, MDS, Clinical Research, Clinical Trials, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric
PAPER

5958 Total body irradiation versus chemotherapy-based myeloablative conditioning in adult patients aged 18–60 years with FLT3-ITD-mutated acute myeloid leukemia in first complete remission undergoing allogeneic hematopoietic cell transplantation: A study from the ALWP of the EBMT

Sarah Kayser, MD, Arnon Nagler I, MD2, Maud Ngoya3, Ibrahim Yakoub-Agha4, Tobias Gedde-Dahl5, Jan Vydra, MD, PhD6, Urpu Salmenniemi, MD7, Mahmoud Aljurf, MD8, Francis Ayuketang Ayuk, MD9, Peter Pal Remenyi, MD10, Dominik Schneidawind, MD, PhD11, Jakob Passweg, MD, MS12, Anna Grassi, MD13, Edouard Forcade, MD, PhD14, Davide Stella15, Luca Castagna, MD16, Matteo Parma17, Regis Peffault De Latour, MD, PhD18, Estefanía Pérez López19, Henrik Sengeloev, MD20, Matthias Stelljes, MD21, Ali Bazarbachi, MD, PhD22, Bipin Savani, MD23, Mohamad Mohty, MD, PhD24, Alexandros Spyridonidis25, Francesco Saraceni, MD26, Frederic Baron, MD27, Fabio Ciceri, MD28, Jaime Sanz, MD, PhD29, Eolia Brissot, MD, PhD30
1 Charité Universitätsmedizin, Berlin, Germany
2 Sheba Medical Center, Tel Hashomer, Israel
3 Sorbonne University, Paris, France
4 CHU de Lille, Lille, France
5 Oslo University Hospital, Oslo, Norway
6 Institute of Hematology and Blood Transfusion, Prague, Czech Republic
7 HUCH Comprehensive Cancer Center, Helsinki, Finland
8 King Faisal Specialist Hospital and Research Center, Riyad, Saudi Arabia
9 University Hospital Eppendorf, Hamburg, Germany
10 Del-pesti Centrumkorhaz, Budapest, Hungary
11 University Hospital Zurich, Zurich, Switzerland
12 University Hospital Basel, Basel, Switzerland
13 ASST Papa Giovanni XXIII, Bergamo, Italy
14 CHU Bordeaux, Pessac, France
15 AOU Città della Salute e della Scienza, Torino, Italy
16 AOR Villa Sofia Cervello, Palermo, Italy
17 IRCCS San Gerardo, Monza, Italy
18 Hôpital Saint Louis, Paris, France
19 Complejo Asistencial Universitario de Salamanca, Salamanca, Spain
20 Rigshospitalet, Copenhagen, Denmark
21 University Hospital Münster, Münster, Germany
22 American University of Beirut Medical Center, Beirut, Lebanon
23 Vanderbilt University Medical Center, Nashville, United States
24 Sorbonne University, Paris, France
25 University of Patras, Patras, Greece
26 Azienda Ospedaliero Universitaria delle Marche, Ancona, Italy
27 University of Liege, Liege, Belgium
28 Ospedale San Raffaele, Milano, Italy
29 University Hospital La Fe, Valencia, Spain
30 Sorbonne University, Paris, France

Background: Allogeneic hematopoietic cell transplantation (allo-HCT) is the standard consolidation strategy for medically fit adults with FLT3-ITD mutated acute myeloid leukemia (AML) in first complete remission (CR1). Historically, FLT3-ITD-mutated AML was considered a high-risk disease, and TBI-based myeloablative conditioning was often favored for these patients. However, following the 2022 European LeukemiaNet (ELN) classification, FLT3-ITD-mutated AML is classified as intermediate risk. Despite the incorporation of FLT3 inhibitors into frontline therapy, relapse after allo-HCT remains a major cause of treatment failure. The optimal myeloablative conditioning (MAC) strategy, using either total body irradiation (TBI)-based or chemotherapy-based regimens, remains uncertain. To date, no study has directly compared these two approaches in adults with FLT3-ITD-mutated AML undergoing allo-HCT in CR1.

Methods: We conducted a retrospective study including adults (18–60 years) with FLT3-ITD-mutated AML in CR1 undergoing first allo-HCT between 2012 and 2025 after TBI- or chemotherapy-based MAC. MAC was defined as conditioning including TBI >6 Gy, total busulfan >8 mg/kg orally or >6.4 mg/kg intravenously, or total treosulfan >36 g/m². Donors were matched sibling, matched (10/10) or mismatched (9/10) unrelated, or haploidentical, and graft sources were peripheral blood or bone marrow. The primary endpoint was overall survival (OS). Secondary endpoints included leukemia-free survival (LFS), graft-versus-host disease (GVHD)-free, relapse-free survival (GRFS), relapse incidence (RI), non-relapse mortality (NRM), and acute (aGVHD) and chronic GVHD (cGVHD). Survival outcomes were estimated using the Kaplan–Meier method, and competing-risk endpoints using cumulative incidence functions. Multivariable models adjusted for donor type, transplant year, patient age, cytomegalovirus (CMV) serostatus, stem cell source, Karnofsky performance status (KPS) score, female donor to male recipient combination, and transplant center.

Results: A total of 2075 patients were included, of whom 259 (12.5%) received TBI-based MAC and 1816 (87.5%) chemotherapy-based MAC. Patients receiving TBI-based MAC were younger than those receiving chemotherapy-based MAC (median age 41.9 vs. 45.8 years, P<0.001), more frequently received matched sibling donor grafts, had a lower KPS score, and differed with regards to transplant year, CMV serostatus, and GVHD prophylaxis, with less frequent use of post-transplant cyclophosphamide and more frequent use of antithymocyte globulin in the TBI group. At 2 years, OS was 72.9% after TBI-based MAC and 74.7% after chemotherapy-based MAC. Corresponding rates of LFS, RI, NRM, and GRFS were 68.2% versus 65.3%, 21.6% versus 25.8%, 10.2% versus 8.9%, and 50.9% versus 54.0%, respectively. Grade II–IV aGVHD was more frequent after TBI-based MAC (33.8% vs. 24.7%, P=0.005). In contrast, the incidences of grade III–IV aGVHD, overall cGVHD, and extensive cGVHD were comparable between groups. After adjustment for donor type, transplant year, patient age, CMV serostatus, stem cell source, KPS, female-to-male donor sex mismatch, and transplant center, TBI-based MAC was not independently associated with OS, LFS, RI, NRM, GRFS, or cGVHD. However, TBI-based MAC remained independently associated with a higher risk of grade II–IV aGVHD (hazard ratio 1.45, 95% CI 1.07–1.97; P=0.02).

Conclusions: In adults with FLT3-ITD-mutated AML undergoing allo-HCT in CR1, TBI-based MAC was not associated with improved survival or better disease control compared with chemotherapy-based MAC. However, TBI-based MAC was associated with a higher risk of grade II–IV acute GVHD, suggesting no overall clinical advantage of TBI in this setting.

Sarah Kayser, MD: No relevant conflicts of interest to declare.